Contract analysis

I. Executive Summary The purpose of this memorandum is to provide a comprehensive analysis of the final indemnification and risk allocation framework embodied in the executed Asset Purchase Agreement, dated as of May 11, 2023 (the "APA"), by and between Genome Dx Therapeutics Inc., a Delaware corporation ("GDT" or "Seller"), and Meridian Precision Diagnostics, Inc., a Delaware corporation ("Meridian" or "Buyer"), pur

II. Transaction Overview A. The Parties Seller. Genome Dx Therapeutics Inc. ("GDT") is a Delaware corporation headquartered at 10250 Science Center Drive, Suite 600, San Diego, California 92121. GDT is a developer and commercializer of genomic profiling assays used in oncology and related precision medicine applications. For the fiscal year ended December 31, 2022, GDT reported total revenue of approximately $312,000

III. Indemnification Cap A. Aggregate Cap on Seller's Liability Pursuant to Section 10.4(a) of the APA, Seller's aggregate indemnification liability for all Losses arising from or related to breaches of Seller's non-fundamental representations, warranties, covenants, and obligations under the APA is capped at twenty percent (20%) of Total Consideration, calculated as follows: $140,000,000 × 20% = $28,000,000 This cap

IV. Survival Periods A. General Representations and Warranties Pursuant to Section 10.1(a) of the APA, all representations and warranties of Seller contained in the APA (other than the Fundamental Representations, Tax Representations, and Environmental Representations, which are addressed separately below) survive the Closing for a period of eighteen (18) months from the Closing Date. Based on the actual Closing Date

V. Basket and De Minimis Threshold A. Aggregate Basket (Tipping)

Section 10.4(c) of the APA establishes an aggregate basket of $1,400,000 (calculated as 1.0% of Total Consideration: $140,000,000 × 1.0% = $1,400,000). The basket is structured as a tipping basket (sometimes referred to as a "first dollar" basket): once the aggregate amount of indemnifiable Losses exceeds the $1,400,000 threshold, Seller becomes liable for the entire amount of such Losses from dollar one — not merely

Section 10.4(d) of the APA establishes a de minimis threshold of $75,000 per individual claim or series of related claims. Losses attributable to any individual claim (or series of related claims arising from the same or substantially similar facts or circumstances) that do not exceed $75,000 are excluded entirely from the indemnification framework and do not count toward — or aggregate for purposes of — the $1,400,0

VI. Escrow Mechanics A. Escrow Deposit Pursuant to Section 2.3(b) of the APA and the Escrow Agreement entered into concurrently with the APA among Seller, Buyer, and Ashgrove Equity Partners Escrow Services, Inc. (the "Escrow Agent"), an amount equal to $14,000,000 (representing 10% of Total Consideration: $140,000,000 × 10% = $14,000,000) was deposited at closing into a segregated escrow account maintained by the Es

VII. Fundamental Representations — Special Treatment The treatment of Fundamental Representations under the APA is summarized in the sections above and warrants a consolidated discussion given the significant differences from the treatment of general representations and warranties: • Extended Survival: Sixty (60) months from the Closing Date, extending through August 8, 2028 — more than three times the 18-month gener

VIII. Representations and Warranties Insurance — Interplay with Indemnification A. Policy Overview In connection with the transaction, a buyer-side representations and warranties insurance policy (the "RWI Policy") has been procured from Apex Mutual Insurance Company. The key terms of the RWI Policy are as follows: The RWI Policy is a buyer-side policy, meaning that Buyer is the named insured and the policy provides

IX. Assumed Liabilities vs. Excluded Liabilities — Risk Boundary A. Assumed Liabilities Pursuant to Section 2.4 of the APA, Buyer assumes the following liabilities in connection with the acquisition of the OncuPath Business (the "Assumed Liabilities"): (i) All trade payables and other current liabilities of the OncuPath Business arising or accruing in the ordinary course of business from and after the Closing Date; (

Section 2.5 of the APA identifies the following liabilities as "Excluded Liabilities," which are retained by Seller and are not assumed by Buyer: (i) All liabilities of the OncuPath Business arising, accruing, or relating to the period prior to the Closing Date, including trade payables, accrued expenses, and other obligations that are attributable to the pre-closing operation of the OncuPath Business (except to the

X. Working Capital Adjustment — Interaction with Indemnification The APA includes a customary post-closing working capital adjustment mechanism, the key terms of which are as follows: • Target Net Working Capital ("NWC"): $6,800,000, determined by reference to the carve-out financial statements of the OncuPath Business prepared by Haverford & Lane LLP for the twelve-month period ended December 31, 2022, and the stub

XI. Benchmarking Against Comparable Biotech Asset Divestitures A. Methodology. To assess the market-consistency and relative favorability of the indemnification package negotiated in the GDT/Meridian APA, we reviewed publicly available data (including SEC filings, industry surveys published by the American Bar Association's Private Target Mergers & Acquisitions Deal Points Study, and the Cascade Advisory Group M&A De

XII. Seller-Specific Risk Considerations A. Carve-Out Complexity The OncuPath Business is being carved out of GDT's broader operations, which introduces a number of complexities that could give rise to post-closing indemnification claims or disputes. During the pre-closing period and for up to nine (9) months following the Closing, GDT will provide Meridian with certain transitional support services pursuant to the T